Get started
Author

Jiansong Ji

Observed names: Jian-Song Ji, Jian-song Ji, JianSong Ji, Jian‐Song Ji
Observed institutions: Fujian Medical University, Capital Medical University, Shaoxing University, Wenzhou Medical University, Beijing Chao-Yang Hospital, Capital Medical University, Sir Run Run Shaw Hospital, Lishui University, Soochow University, Ningbo No. 2 Hospital, Zhongda Hospital Southeast University, Lishui Central Hospital, Lishui City People's Hospital, First Affiliated Hospital of Soochow University, First Hospital of Lanzhou University, Zhejiang University, Southeast University, Nanjing Medical University
ORCID: 0000-0003-4727-2794
Observed ORCIDs: 0000-0003-4727-2794, 0000-0001-6975-620X
OpenAlex ID: A5115600007
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
2020 · Jin-Yu Sun, Dengke Zhang, et al. · Biomarker Research · 280
PDF
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
2019 · Minjiang Chen, Aiwu Mao, et al. · Cancer Letters · 270
Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases
2019 · Yunbin Zhang, Jingjing Song, et al. · Cancer Letters · 210
Delivery strategies of cancer immunotherapy: recent advances and future perspectives
2019 · Zhongwei Zhao, Liyun Zheng, et al. · Journal of Hematology & Oncology · 177
PDF
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
2024 · Zhi-Cheng Jin, Jian-Jian Chen, et al. · EClinicalMedicine · 161
Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial
2014 · Hai-Dong Zhu, Jin-He Guo, et al. · The Lancet Oncology · 150
Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival
2016 · Jian-Fei Tu, Ya-Hui Ding, et al. · Scientific Reports · 144
PDF
T-cell-based immunotherapy in colorectal cancer
2020 · Mei Feng, Zhongwei Zhao, et al. · Cancer Letters · 107
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
2019 · Weiqi Xu, Ken Liu, et al. · Therapeutic Advances in Medical Oncology · 105
PDF
Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
2021 · Liyun Zheng, Shiji Fang, et al. · Frontiers in Molecular Biosciences · 90
PDF
Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells
2015 · Xiuhua Zhang, Minxiao Chen, et al. · BMC Cancer · 85
PDF
HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma
2022 · Minjiang Chen, Gaofeng Shu, et al. · Biomaterials · 70
Retracted: Global microarray profiling identified hsa_circ_0064428 as a potential immune-associated prognosis biomarker for hepatocellular carcinoma
2018 · Qiaoyou Weng, Minjiang Chen, et al. · Journal of Medical Genetics · 70
Sophoridine suppresses lenvatinib‐resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression
2020 · Zhongwei Zhao, Dengke Zhang, et al. · Journal of Cellular and Molecular Medicine · 66
PDF
NEAT1 upregulates TGF‐β1 to induce hepatocellular carcinoma progression by sponging hsa‐mir‐139‐5p
2018 · Jianfei Tu, Zhongwei Zhao, et al. · Journal of Cellular Physiology · 64
Sweetener aspartame aggravates atherosclerosis through insulin-triggered inflammation
2025 · Weijie Wu, Wenhai Sui, et al. · Cell Metabolism · 62
Chemopreventive effect of chalcone derivative, L2H17, in colon cancer development
2015 · Shanmei Xu, Minxiao Chen, et al. · BMC Cancer · 53
PDF
LINC00460 promotes hepatocellular carcinoma development through sponging miR-485-5p to up-regulate PAK1
2019 · Jianfei Tu, Zhongwei Zhao, et al. · Biomedicine & Pharmacotherapy · 50
PDF
Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
2020 · Xiang-Pan Meng, Yuan-Cheng Wang, et al. · Frontiers in Oncology · 48
PDF
MicroRNA‐27a‐3p inhibits cell viability and migration through down‐regulating DUSP16 in hepatocellular carcinoma
2017 · Jin‐Mao Li, Jun Zhou, et al. · Journal of Cellular Biochemistry · 46
Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study
2021 · Zhicheng Jin, Li Chen, et al. · Translational Oncology · 41
PDF
Long Non-Coding RNA PCAT6 Induces M2 Polarization of Macrophages in Cholangiocarcinoma via Modulating miR-326 and RhoA-ROCK Signaling Pathway
2021 · Jianfei Tu, Fazong Wu, et al. · Frontiers in Oncology · 41
PDF
The identification of a common different gene expression signature in patients with colorectal cancer
2019 · Zhongwei Zhao, Xiaoxi Fan, et al. · Mathematical Biosciences & Engineering · 39
Macrophage infiltration promotes invasiveness of breast cancer cells via activating long non-coding RNA UCA1.
2015 · Shuzheng Chen, Chuxiao Shao, et al. · PubMed · 39
Management of patients with intermediate stage hepatocellular carcinoma
2020 · David Prince, Ken Liu, et al. · Therapeutic Advances in Medical Oncology · 38
Works count: 132
Citation count: 3,471
H-index: 30
I10-index: 69
Year
Topic
Type